Table 1

Patient characteristics

Subjects, n27
Median age, y (range)
    Recipient52 (19-67)
    Donor39 (24-65)
Sex
    Male11
    Female16
Race
    White19
    Black6
    Asian2
Disease and disease status at HSCT
    AML CR1 with high-risk features*5
    AML CR22
    AML primary induction failure2
    AML in resistant relapse7
    Biphenotypic leukemia with disease at HSCT1
    ALL CR2 (Ph)3
    ALL (Ph+) morphologic remission1
    MDS2
    NHL chemotherapy resistant3
    Aplastic anemia1
    Previous transplant2
    Secondary malignancy2
Recipient/donor transplantation combinations
    Sibling-to-sibling7
    Parent-to-child4
    Child-to-parent16
CMV serostatus recipient (R) and donor (D)
    R+/D+12
    R+/D6
    R/D9
HLA antigen mismatches (GVH direction) (A, B, Cw, DRB1), n
    413
    311
    22
    01
KIR mismatches
    HLA-C group 15
    HLA-C group 24
    HLA-Bw41
    HLA-C and HLA-Bw42
    No KIR mismatch15
  • * Based on cytogenetics, secondary disease, CNS/tissue involvement, or arising from MDS.

  • Patient had 4 mismatches in HVG direction only and was counted for toxicity only

  • KIR ligand missing in recipient but present in donor. Missing self as defined by Ruggeri et al.18

  • AML indicates acute myeloid leukemia; CR, complete remission; Ph, Philadelphia chromosome; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; and NHL, nonHodgkin lymphoma.